Tessera Therapeutics joins Sania Therapeutics, Editas Medicine, and Affinia Therapeutics at the American Society of Gene & Cell Therapy 2024 Annual Meeting.

Tessera Therapeutics to present new preclinical data on in vivo therapies targeting genetic diseases and T-cell based therapies.

Highlights include RNA-based gene writing, lipid nanoparticle delivery, and gene editing for sickle cell and Wilson's disease mutations.

Presentations from all participating companies will be accessible on their websites during the conference.